MA37765A1 - Composés de pyrazole substitués utilisés comme antagonistes de lpar - Google Patents

Composés de pyrazole substitués utilisés comme antagonistes de lpar

Info

Publication number
MA37765A1
MA37765A1 MA37765A MA37765A MA37765A1 MA 37765 A1 MA37765 A1 MA 37765A1 MA 37765 A MA37765 A MA 37765A MA 37765 A MA37765 A MA 37765A MA 37765 A1 MA37765 A1 MA 37765A1
Authority
MA
Morocco
Prior art keywords
compounds used
pyrazole compounds
substituted pyrazole
lpar antagonists
lpar
Prior art date
Application number
MA37765A
Other languages
English (en)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37765(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA37765A1 publication Critical patent/MA37765A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des composés de formule (i) ainsi que des sels pharmaceutiquement acceptables de ceux-ci, les substituants étant ceux qui sont indiqués dans la description. Ces composés, et les compositions pharmaceutiques les contenant, sont utiles pour le traitement de maladies et de troubles inflammatoires tels que le fibrose pulmonaire par exemple.
MA37765A 2012-06-20 2013-06-17 Composés de pyrazole substitués utilisés comme antagonistes de lpar MA37765A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20
PCT/EP2013/062458 WO2013189862A1 (fr) 2012-06-20 2013-06-17 Composés de pyrazole substitués utilisés comme antagonistes de lpar

Publications (1)

Publication Number Publication Date
MA37765A1 true MA37765A1 (fr) 2017-04-28

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37765A MA37765A1 (fr) 2012-06-20 2013-06-17 Composés de pyrazole substitués utilisés comme antagonistes de lpar

Country Status (22)

Country Link
US (1) US20150259295A1 (fr)
EP (1) EP2864294A1 (fr)
JP (1) JP2015520201A (fr)
KR (1) KR20150011003A (fr)
CN (1) CN104411690A (fr)
AU (1) AU2013279510A1 (fr)
BR (1) BR112014031108A2 (fr)
CA (1) CA2869602A1 (fr)
CL (1) CL2014003242A1 (fr)
CO (1) CO7160077A2 (fr)
CR (1) CR20140516A (fr)
EA (1) EA201492283A1 (fr)
HK (1) HK1206341A1 (fr)
IL (1) IL236091A0 (fr)
IN (1) IN2014DN09347A (fr)
MA (1) MA37765A1 (fr)
MX (1) MX2014014105A (fr)
PE (1) PE20142445A1 (fr)
PH (1) PH12014502364A1 (fr)
SG (1) SG11201407229UA (fr)
UA (1) UA109867C2 (fr)
WO (1) WO2013189862A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014003499A2 (pt) 2011-08-15 2017-06-13 Intermune Inc compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula
DK2988743T3 (da) 2013-03-15 2021-03-01 Epigen Biosciences Inc Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
CA2953472C (fr) 2014-06-27 2022-08-02 Ube Industries, Ltd. Sel d'un compose heterocyclique substitue par un groupe halogeno
MX2020005874A (es) * 2017-12-19 2020-08-13 Bristol Myers Squibb Co Acidos carbamoil ciclohexilicos n-enlazados a pirazol como antagonistas de receptores del acido lisofosfatidico (lpa).
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
CA3158743A1 (fr) 2019-11-15 2021-05-20 Gilead Sciences, Inc. Pyridylsulfonamides de carbamate de triazole utilisees en tant qu'antagonistes du recepteur de lpa et leurs utilisations
CN115867556A (zh) 2020-06-03 2023-03-28 吉利德科学公司 Lpa受体拮抗剂及其用途
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CN117295717A (zh) * 2021-05-11 2023-12-26 吉利德科学公司 Lpa受体拮抗剂及其用途
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698335A4 (fr) * 2003-12-26 2007-08-01 Ono Pharmaceutical Co Agent pour prevenir et/ou de traiter des maladies faisant intervenir un recepteur de benzodiazepine mitochondrial
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN00754A (fr) * 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
JP2014508111A (ja) * 2010-12-07 2014-04-03 アミラ ファーマシューティカルス，インコーポレーテッド リゾフォスファチジン酸受容体アンタゴニスト、その線維症の治療における使用
WO2012138648A1 (fr) * 2011-04-06 2012-10-11 Irm Llc Compositions et procédés pour la modulation de récepteurs au lpa
BR112014003499A2 (pt) * 2011-08-15 2017-06-13 Intermune Inc compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula

Also Published As

Publication number Publication date
CO7160077A2 (es) 2015-01-15
HK1206341A1 (en) 2016-01-08
US20150259295A1 (en) 2015-09-17
EP2864294A1 (fr) 2015-04-29
CL2014003242A1 (es) 2015-03-20
PE20142445A1 (es) 2015-01-28
IL236091A0 (en) 2015-02-01
KR20150011003A (ko) 2015-01-29
BR112014031108A2 (pt) 2017-06-27
CA2869602A1 (fr) 2013-12-27
UA109867C2 (ru) 2015-10-12
JP2015520201A (ja) 2015-07-16
AU2013279510A1 (en) 2014-10-16
IN2014DN09347A (fr) 2015-07-17
EA201492283A1 (ru) 2015-04-30
CN104411690A (zh) 2015-03-11
SG11201407229UA (en) 2014-12-30
WO2013189862A1 (fr) 2013-12-27
CR20140516A (es) 2014-12-01
PH12014502364A1 (en) 2015-01-12
MX2014014105A (es) 2015-03-05

Similar Documents

Publication Publication Date Title
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA38398B1 (fr) Composés biaryle amides en tant qu'inhibiteurs de kinase
MA35285B1 (fr) Indazoles
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA35576B1 (fr) Nouveaux composés
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA54386B1 (fr) Modulateurs de trex1
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA35271B1 (fr) Antagonistes de trpm8 et leur utilisation dans des traitements
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
EA201490618A1 (ru) Замещенные 2-(хроман-6-илокси)тиазолы и их пременение в качестве фармацевтических средств
MA38206A1 (fr) Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées
MA38207A2 (fr) Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées
MA45867B1 (fr) Modulateurs du récepteur des oestrogènes